MELINTA THE ANTIBIOTICS COMPANY Trademark

Trademark Overview

On Thursday, July 9, 2015, a trademark application was filed for MELINTA THE ANTIBIOTICS COMPANY with the United States Patent and Trademark Office. The USPTO has given the MELINTA THE ANTIBIOTICS COMPANY trademark a serial number of 86688547. The federal status of this trademark filing is SECTION 8 & 15 - ACCEPTED AND ACKNOWLEDGED as of Saturday, October 8, 2022. This trademark is owned by Melinta Therapeutics, Inc.. The MELINTA THE ANTIBIOTICS COMPANY trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

drug discovery services; research and development of antibiotics
melinta the antibiotics company

General Information

Serial Number86688547
Word MarkMELINTA THE ANTIBIOTICS COMPANY
Filing DateThursday, July 9, 2015
Status702 - SECTION 8 & 15 - ACCEPTED AND ACKNOWLEDGED
Status DateSaturday, October 8, 2022
Registration Number4939738
Registration DateTuesday, April 19, 2016
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, February 2, 2016

Trademark Statements

Disclaimer with Predetermined Text"THE ANTIBIOTICS COMPANY"
Goods and Servicesdrug discovery services; research and development of antibiotics

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateTuesday, July 14, 2015
Primary Code042
First Use Anywhere DateThursday, October 10, 2013
First Use In Commerce DateThursday, October 10, 2013

Trademark Owner History

Party NameMELINTA SUBSIDIARY CORP.
Party Type31 - New Owner After Registration
Legal Entity Type03 - Corporation
AddressMorristown, NJ 07960
Party NameMelinta Therapeutics, Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressNew Haven, CT 06511
Party NameMelinta Therapeutics, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNew Haven, CT 06511
Party NameMelinta Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew Haven, CT 06511

Trademark Events

Event DateEvent Description
Wednesday, October 19, 2022ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Saturday, October 8, 2022NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
Saturday, October 8, 2022REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
Saturday, October 8, 2022CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Monday, April 11, 2022TEAS SECTION 8 & 15 RECEIVED
Monday, April 19, 2021COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Wednesday, January 13, 2021ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Wednesday, July 29, 2020APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Wednesday, July 29, 2020TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, July 29, 2020ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Wednesday, July 29, 2020TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Wednesday, July 29, 2020TEAS CHANGE OF OWNER ADDRESS RECEIVED
Wednesday, May 30, 2018AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Tuesday, April 19, 2016REGISTERED-PRINCIPAL REGISTER
Tuesday, February 2, 2016OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, February 2, 2016PUBLISHED FOR OPPOSITION
Wednesday, January 13, 2016NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Thursday, October 22, 2015APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, October 21, 2015EXAMINER'S AMENDMENT ENTERED
Wednesday, October 21, 2015NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Wednesday, October 21, 2015EXAMINERS AMENDMENT E-MAILED
Wednesday, October 21, 2015EXAMINERS AMENDMENT -WRITTEN
Monday, October 19, 2015ASSIGNED TO EXAMINER
Tuesday, July 14, 2015NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Monday, July 13, 2015NEW APPLICATION ENTERED IN TRAM

Related Keywords

company antibiotics melinta development research services discovery drug